CHICAGO, May 9 (Reuters) - St. Jude Medical Inc STJ.N on Wednesday said it won approval from the U.S. Food and Drug Administration for its new pacing lead.
The company said the lead, which attaches to a cardiac pacemaker, is the first of its kind, designed to provide more accurate sensing of the right atrium, the upper chamber of the heart.
The lead incorporates a new tip that reduces extraneous signals from the heart’s ventricles, or the lower chambers, that can interfere with a pacemaker’s sensing capabilities.
((Reporting by Debra Sherman; Editing by Derek Caney; Reuters Messaging: email@example.com; debra. firstname.lastname@example.org, 1-312-408-8134)) Keywords: STJUDE FDA/
C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN7892